Janelidze, S., Collij, L. E., Mattsson-Carlgren, N., Antill, A., Laymon, C. M., Lott, I., Rosas, H. D., Minhas, D. S., Luo, W., Zaman, S., Mapstone, M., Head, E., Lai, F., Hartley, S. L., Ances, B. M., Krinsky-McHale, S. J., Lee, J. H., Ossenkoppele, R., Christian, B. T., … Hansson, O. (2025). Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study. The Lancet Neurology, 24(7), 591–600. https://doi.org/10.1016/s1474-4422(25)00158-9

Bateman, R. J., Li, Y., McDade, E. M., Llibre-Guerra, J. J., Clifford, D. B., Atri, A., Mills, S. L., Santacruz, A. M., Wang, G., Supnet, C., Benzinger, T. L. S., Gordon, B. A., Ibanez, L., Klein, G., Baudler, M., Doody, R. S., Delmar, P., Kerchner, G. A., Bittner, T., … Schofield, P. R. (2025). Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. The Lancet Neurology, 24(4), 316–330. https://doi.org/10.1016/s1474-4422(25)00024-9

Moens, T. G., Da Cruz, S., Neumann, M., Shelkovnikova, T. A., Shneider, N. A., & Van Den Bosch, L. (2025). Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications. The Lancet Neurology, 24(2), 166–178. https://doi.org/10.1016/s1474-4422(24)00517-9

Coleman, K. K. L., Berry, S., Cummings, J., Hsiung, G.-Y. R., Laforce, R., Huey, E., Ducharme, S., Tartaglia, M. C., Mendez, M. F., Onyike, C., Domoto-Reilly, K., Masellis, M., Herrmann, N., Porsteinsson, A., Detry, M. A., Stewart, C., Bosse, A. L., McGlothlin, A., Dias, B., … Finger, E. C. (2025). Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial. The Lancet Neurology, 24(2), 128–139. https://doi.org/10.1016/s1474-4422(24)00456-3

Ma, Y., Farris, C. M., Weber, S., Schade, S., Nguyen, H., Pérez-Soriano, A., Giraldo, D. M., Fernández, M., Soto, M., Cámara, A., Painous, C., Muñoz, E., Valldeoriola, F., Martí, M. J., Clarimon, J., Kallunki, P., Ma, T. C., Alcalay, R. N., Gomes, B. F., … Concha-Marambio, L. (2024). Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. The Lancet Neurology, 23(12), 1225–1237. https://doi.org/10.1016/s1474-4422(24)00395-8

Andrews, J. A. (2024). A new era of drug discovery for amyotrophic lateral sclerosis. The Lancet Neurology, 23(11), 1070–1072. https://doi.org/10.1016/s1474-4422(24)00407-1

Wisch, J. K., McKay, N. S., Boerwinkle, A. H., Kennedy, J., Flores, S., Handen, B. L., Christian, B. T., Head, E., Mapstone, M., Rafii, M. S., O’Bryant, S. E., Price, J. C., Laymon, C. M., Krinsky-McHale, S. J., Lai, F., Rosas, H. D., Hartley, S. L., Zaman, S., Lott, I. T., … Mori, H. (2024). Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer’s disease: a cross-sectional study. The Lancet Neurology, 23(5), 500–510. https://doi.org/10.1016/s1474-4422(24)00084-x

Valentino, R. R., Scotton, W. J., Roemer, S. F., Lashley, T., Heckman, M. G., Shoai, M., Martinez-Carrasco, A., Tamvaka, N., Walton, R. L., Baker, M. C., Macpherson, H. L., Real, R., Soto-Beasley, A. I., Mok, K., Revesz, T., Christopher, E. A., DeTure, M., Seeley, W. W., Lee, E. B., … Wszolek, Z. K. (2024). MAPT H2 haplotype and risk of Pick’s disease in the Pick’s disease International Consortium: a genetic association study. The Lancet Neurology, 23(5), 487–499. https://doi.org/10.1016/s1474-4422(24)00083-8

Tausch, A., Thakur, K. T., & Oliveira e Souza, R. (2024). Addressing neurological burden in the Americas. The Lancet Neurology, 23(4), 327–328. https://doi.org/10.1016/s1474-4422(24)00085-1

Giladi, N., Alcalay, R. N., Cutter, G., Gasser, T., Gurevich, T., Höglinger, G. U., Marek, K., Pacchetti, C., Schapira, A. H. V., Scherzer, C. R., Simuni, T., Minini, P., Sardi, S. P., & Peterschmitt, M. J. (2023). Safety and efficacy of venglustat in GBA1-associated Parkinson’s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology, 22(8), 661–671. https://doi.org/10.1016/s1474-4422(23)00205-3

Siderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., Nguyen, H., Alcalay, R. N., Chahine, L. M., Foroud, T., Galasko, D., Kieburtz, K., Merchant, K., Mollenhauer, B., Poston, K. L., Seibyl, J., Simuni, T., Tanner, C. M., Weintraub, D., … Soto, C. (2023). Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. The Lancet Neurology, 22(5), 407–417. https://doi.org/10.1016/s1474-4422(23)00109-6

Boerwinkle, A. H., Gordon, B. A., Wisch, J., Flores, S., Henson, R. L., Butt, O. H., McKay, N., Chen, C. D., Benzinger, T. L. S., Fagan, A. M., Handen, B. L., Christian, B. T., Head, E., Mapstone, M., Rafii, M. S., O’Bryant, S., Lai, F., Rosas, H. D., Lee, J. H., … Xu, X. (2023). Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer’s disease: a cross-sectional study. The Lancet Neurology, 22(1), 55–65. https://doi.org/10.1016/s1474-4422(22)00408-2

Egbebike, J., Shen, Q., Doyle, K., Der-Nigoghossian, C. A., Panicker, L., Gonzales, I. J., Grobois, L., Carmona, J. C., Vrosgou, A., Kaur, A., Boehme, A., Velazquez, A., Rohaut, B., Roh, D., Agarwal, S., Park, S., Connolly, E. S., & Claassen, J. (2022). Cognitive-motor dissociation and time to functional recovery in patients with acute brain injury in the USA: a prospective observational cohort study. The Lancet Neurology, 21(8), 704–713. https://doi.org/10.1016/s1474-4422(22)00212-5

Nath, A., Smith, B. R., & Thakur, K. T. (2022). Major advances in neuroinfectious diseases in the past two decades. The Lancet Neurology, 21(4), 308–310. https://doi.org/10.1016/s1474-4422(22)00093-x

Gutierrez, J., Turan, T. N., Hoh, B. L., & Chimowitz, M. I. (2022). Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. The Lancet Neurology, 21(4), 355–368. https://doi.org/10.1016/s1474-4422(21)00376-8

Chhatwal, J. P., Schultz, S. A., McDade, E., Schultz, A. P., Liu, L., Hanseeuw, B. J., Joseph-Mathurin, N., Feldman, R., Fitzpatrick, C. D., Sparks, K. P., Levin, J., Berman, S. B., Renton, A. E., Esposito, B. T., Fernandez, M. V., Sung, Y. J., Lee, J. H., Klunk, W. E., Hofmann, A., … Sperling, R. A. (2022). Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study. The Lancet Neurology, 21(2), 140–152. https://doi.org/10.1016/s1474-4422(21)00375-6

Palta, P., Albert, M. S., & Gottesman, R. F. (2021). Heart health meets cognitive health: evidence on the role of blood pressure. The Lancet Neurology, 20(10), 854–867. https://doi.org/10.1016/s1474-4422(21)00248-9

Cortese, I., Beck, E. S., Al-Louzi, O., Ohayon, J., Andrada, F., Osuorah, I., Dwyer, J., Billioux, B. J., Dargah-zada, N., Schindler, M. K., Binder, K., Reoma, L., Norato, G., Enose-Akahata, Y., Smith, B. R., Monaco, M. C., Major, E. O., Jacobson, S., Stroncek, D., … Muranski, P. (2021). BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. The Lancet Neurology, 20(8), 639–652. https://doi.org/10.1016/s1474-4422(21)00174-5

Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E., Christian, B. T., Lai, F., Rosas, H. D., Schupf, N., Krinsky-McHale, S., Silverman, W., Lee, J. H., Klunk, W. E., Handen, B. L., Allegri, R. F., … Lott, I. T. (2021). Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer’s disease: a cross-sectional study. The Lancet Neurology, 20(8), 615–626. https://doi.org/10.1016/s1474-4422(21)00139-3